

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Previously presented) A method for reducing the number of viable cancer cells in a mammal, comprising administering attenuated measles virus to said mammal under conditions wherein the number of viable cancer cells in said mammal is reduced.
2. (Previously presented) The method of claim 1, wherein said attenuated measles virus is administered directly to a cancer cell in said mammal.
3. (Previously presented) The method of claim 2, wherein said cancer cell is part of a tumor.
4. (Previously presented) The method of claim 3, wherein said attenuated measles virus is injected directly into said tumor.
5. (Previously presented) The method of claim 4, wherein said attenuated measles virus is provided in a formulation comprising an excipient.
6. (Previously presented) The method of claim 5, wherein said attenuated measles virus formulation is provided continuously to said mammal.
7. (Previously presented) The method of claim 5, wherein said attenuated measles virus formulation is provided in pulses to said mammal.

8. (Cancelled).
9. (Previously presented) The method of claim 1, wherein said attenuated measles virus is administered systemically to said mammal.
10. (Cancelled).
11. (Previously presented) The method of claim 1, wherein said attenuated measles virus is administered at a dose greater than about 10^3 pfu.
12. (Previously presented) The method of claim 11, wherein said dose is about 10^5 pfus.
13. (Previously presented) The method of claim 11, wherein said dose is about 10^6 pfus.
14. (Previously presented) The method of claim 11, wherein said dose is about 10^7 pfus.
15. (Previously presented) The method of claim 11, wherein said dose is about 10^8 pfus.
16. (Previously presented) The method of claim 1, wherein said attenuated measles virus is provided in a composition further comprising attenuated mumps virus and attenuated rubella virus.
17. (Previously presented) The method of claim 1, wherein said attenuated measles virus is provided in a composition further comprising attenuated rubella virus.
18. (Previously presented) The method of claim 1, wherein said attenuated measles virus is genetically modified to express a marker polypeptide, and wherein expression of said marker polypeptide correlates with replication of said attenuated measles virus.

19. (Original) The method of claim 18, wherein said marker polypeptide is β -galactosidase or Green Fluorescent Protein.
20. (Previously presented) The method of claim 1, wherein said cancer cells are selected from the group consisting of melanoma cells, carcinoma cells, glioma cells, and myeloma cells.
21. (Previously presented) The method of claim 20, wherein said cancer cells are myeloma cells.
22. (Previously presented) The method of claim 21, wherein said myeloma cells are Non-Hodgkin's Lymphoma cells.
23. (Cancelled).
24. (Original) The method of claim 1, wherein said attenuated measles virus is provided within a vaccine formulation.
25. (Cancelled).
26. (Original) The method of claim 24, wherein said vaccine is the MMR-II vaccine.
27. (Cancelled).
28. (Previously presented) The method of claim 1, wherein said attenuated virus is selected from the group consisting of the Edmonston Zagreb measles strain, the Edmonston-Enders strain, the Moraten strain, and the Moraten Berna strain.

29. (Previously presented) The method of claim 1, wherein said attenuated virus comprises a strain obtained after serial passage of either the Moraten strain or the Moraten Berna strain on non-human cells.
30. (Previously presented) The method of claim 1, wherein said attenuated virus comprises a strain obtained after serial passage of the Edmonston strain, the Edmonston Zagreb strain, or the Edmonston Enders strain on non-human cells.
31. (Original) The method of claim 1, wherein said attenuated virus comprises at least one point mutation in a wild-type or attenuated measles virus genome.
32. (Original) The method of claim 31, wherein said attenuated virus does not comprise contiguous point mutations.
33. (Previously presented) The method of claim 11, wherein said dose is about 10^{12} pfu.